Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2020 | Comparability of next generation gene panel assays in CLL

Richard Rosenquist • 23 Jun 2020
EHA 2020
Chronic Lymphocytic Leukemia Leukemia

Richard Rosenquist Brandell, MD, of Karolinska Institute, Solna, Stockholm, reviews the comparability of various next-generation gene panel assays in identifying mutations in chronic lymphocytic leukemia (CLL) patients. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Richard Rosenquist

1:50
The impact of IGHV mutational status in treatment decisions in CLL
Richard Rosenquist • 7 Oct 2022
1:26
Common genetic tests in CLL & when these tests should be performed
Richard Rosenquist • 7 Oct 2022
1:31
Using genomics to better understand the pathogenesis of CLL & for early disease diagnosis
Richard Rosenquist • 7 Oct 2022
1:38
The importance of TP53 in CLL
Richard Rosenquist • 7 Oct 2022

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals